Together, these estrogen-mediated pro-angiogenic effects align with preclinical and clinical evidence, where a positive correlation between ER expression, angiogenic activity, tumor size, and invasiveness was observed for several cancer types, including breast cancer and lung cancer [350, 370–372]. The gene discussed is ESR1; the disease is breast carcinoma.